Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 765-777

  Alam, Samina ^a   Bromberg White, Jennifer ^a   McLaughlin Drubin, Margaret ^a   Sen, Ellora ^a   Bodily, Jason M ^a   Meyers, Craig ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense; Human papillomavirus; Oncogenes; Raft cultures; Replication

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE ORI 1001; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BINDING; DRUG STABILITY; DYSPLASIA; EPITHELIUM CELL; GENE AMPLIFICATION; HIGH RISK POPULATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31B; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAFT CULTURE SYSTEM; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; VIRUS TYPING; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOPATHOGENIC EFFECT, VIRAL; DOWN-REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENES, REPORTER; GENOME, VIRAL; HUMANS; LUCIFERASES; OLIGONUCLEOTIDES, ANTISENSE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

EID: 17444433000     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Shah KV and Howley PM: Papillomaviruses, In: B.N. Fields, D.M. Knipe and M. Howley (eds.), Fields Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA. p 2077-2109, 1996.
2. Dell G and Gaston K: Human Papillomaviruses and their role in cervical cancer. Cell Mol Life Sci 58: 1923-42, 2001.
3. Sisk EA and Robertson ES: Clinical Implications of human papillomavirus infection. Front Biosci 1: 7:E77-84, 2002.
4. Lowy DR, Kirnbauer R and Schiller JT: Genital human papillomavirus in anogenital cancer. Proc Acad Sci USA 91: 2436-2440, 1994.
5. zur Hausen H: Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: 55-78, 1996.
6. Severson J, Evans TY, Lee P, Chann T-S, Arany I and Tyring SK: Human Papillomavirus infections: Epidemiology, Pathogenesis and Therapy. J Cutan Med Surg 5: 43-60, 2001.
7. Bubenik J: Animal models for development of therapeutics HPV vaccines. Int J Oncol 20: 207-12, 2002.
8. Schiller JT and Lowy DR: Papillomavirus-like particles based vaccines, cervical cancer and beyond. Expert Opinion in Biol Ther 1: 571-8, 2001.
9. Wraight CJ and White PJ: Antisense oligonucleotides in cutaneous therapy. Pharm Therap 90: 89-104, 2001.
10. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A and Mark GE: Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243: 1354-1356, 1989.
11. Mukhopadhyay T, Tainsky MM, Cavender AC and Roth JA: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51: 1744-1748, 1991.
12. Zamecnik PC and Stephenson ML: Inhibition of Rous Sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc Natl Acad Sci USA 75: 280-284, 1978.
13. Agris CH, Blake KR, Miller PS, Reddy MP and Ts'o POP: Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodexoxyribonucleoside methylphosphonates. Biochemistry 25: 6268-6275, 1986.
14. Smith CC, Aurelian L, Reddy M, Miller PS and Ts'o POP: Antiviral effect of an oligo (nucleotide methylphosphonate) complementary to the splice-junction of herpes simplex virus type-1 immediate early pre-mRNAs 4 and 5. Biochemistry 83: 2787-2791, 1986.
15. Gao WY, Stein CA, Cohen JS, Dutschman GE and Cheng YC: Effect of phosphorothionate homo-oligodeoxynucleotides on herpes simplex virus type 2- induced DNA polymerase. J Biol Chem 264: 11521-11526, 1989.
16. Zerial A, Thuong NT and Helene C: Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res 15: 9909-9919, 1987.
17. Von Ruden T and Gilboa E: Inhibition of human T-cell leukemia virus type 1 replication in primary human T cells that express antisense RNA. J Virol 63: 677-682, 1989.
18. Zamecnik PC, Goodchild J, Taguchi Y and Sarin PS: Inhibition of replication and expression of human T-cell lymphotropic virus type II in cultures cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 83: 4143-4146, 1986.
19. Stein CA, Matsukura M, Subasinghe C, Broder S and Cohen JS: Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res Hum Retroviruses 5: 639-646, 1989.
20. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zelser R, Stec W and Stein CA: Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P- chirality independent. Nucleic Acids Res 23: 4239-4245, 1995.
21. Archambault D, Stein CA and Cohen JS: Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses. Arch Virol 139: 97-109, 1994. Erratum: Arch Virol 140: 809, 1995.
22. Archambault D, Stein CA and Cohen JS: Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses. Arch Virol 139: 97-109, 1994. Erratum: Arch Virol 140: 809, 1995.
23. Anderson KP, Fox MC, Brown-Driver V, Martin MJ and Azad RF: Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate early RNA. Antimicrob Agents Chemother 40: 2004-2011, 1996.
24. Azad RF, Brown-Driver V, Tanaka K, Crooke RM and Anderson KP: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 37: 1945-1954, 1993.
25. Crooke ST: Vitravene-another piece in the mosaic. Antisense Nucleic Acid Drug Dev 8: vii-viii, 1998.
26. Marwick C: First "antisense" drug will treat CMV retinitis. JAMA 280: 871, 1998.
27. Mulamba GB, Hu A, Azad RF, Anderson KP and Coen DM: Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother 42: 971-973, 1998.
28. Cowsert LM, Fox MC, Zon G and Mirabelli CK: In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of Papillomavirus: Potential treatment for genital warts. Antimicrob Agents Chemother 37: 171-177, 1993.
29. Lewis EJ, Agrawal S, Bishop J, Chadwick J, Cristensen ND, Cuthill S, Dunford P, Field A, Francis J, Gibson V, Greenham AK, Kelly F, Kilkushie R, Kreider JW, Mills JS, Mulqueen M, Roberts NA, Roberts P and Szymkowski DE: Non-specific antiviral acitivity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res 48: 187-196, 2000.
30. Steele C, Cowsert LM and Shillitoe EJ: The effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 53: 1-8, 1993.
31. Storey A, Oates D, Banks L, Crawford L and Crook T: Antisense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucl Acids Res 19: 4109-4114, 1991.
32. Iyer RP, Marquis J and Bonnez W: ORI-1001: Antipapilloma virus oligonucleotide. Drugs of the Future 27: 546-557, 2002.
33. Von Knebel, Doeberitz M, Oltersdorf T, Schwarz E and Gissman L: Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48: 3780-3786, 1988.
34. Shillitoe EJ and Steele C: Inhibition of the transformed phenotype of carcinoma cells that contain human papillomavirus. Ann NY Acad Sci 660: 286-287, 1992.
35. Steele C, Sacks PG, Adler-Storthz K and Shillitoe EJ: Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res 52: 4706-4711, 1992.
36. Meyers C and Laimins LA: In vitro model systems for the study of HPV-induced neoplasia. Papillomavirus Res 3: 1-3. 1992.
37. Meyers C, Mayer TJ and Ozbun MA: Synthesis of infectious human papillomavirus Type 18 in differentiating epithelium transfected with viral DNA. J Virol 71: 7381-7386, 1997.
38. Meyers C, Frattini MG, Hudson JB and Laimins LA: Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257: 971-973, 1992.
39. Ozbun MA and Meyers C: Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. J Virol 72: 2715-2722, 1998.
40. Ozbun MA and Meyers C: Human Papillomavirus Type 31b E1 and E2 transcript expression correlates with vegetative viral genome amplification. Virology 248: 218-230, 1998.
41. Meyers C, Bromberg-White JL, Zhong J, Kaupas ME, Bryan JT, Lowe RS and Jansen KU: Infectious virions produced from a human papillomavirus Type 18/16 genomic DNA chimera. J Virol 76: 4723-4733, 2002.
42. Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR and Chow LT: Viral E1 and E2 proteins support replication of homologous and heterologous papilloma viral origins. Proc Natl Acad Sci USA 89: 5799-5803, 1992.
43. Frattini MG and Laimins LA: The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b. Virology 204: 799-804, 1994.
44. Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks, GD and Laimins LA: Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol 65: 2254-2260, 1991.
45. Stanley MA, Browne HM, Appleby M and Minson AC: Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 43: 672-6, 1989.
46. McCance DJ, Kopan R, Fuchs E and Laimins LA: Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci USA 85: 7169-7173, 1988.
47. Meyers C: Organotypic (raft) culture system for the differentiation- dependent replication of papillomavirus. Methods Cell Sci 18: 201-210, 1996.
48. Ozbun MA and Meyers C: Characterization of late gene transcripts expressed during vegetative replication of human papilloraavirus type 31b. J Virol 71: 5161-72, 1997.
49. Ozbun MA and Meyers C: Transforming growth factor β1 induces differentiation in human papillomavirus-positive keratinocytes. J Virol 70: 5437-5446, 1996.
50. Hummel M, Hudson JB and Laimins LA: Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J Virol 66: 6070-6080, 1992.
51. Steele BK, Meyers C and Ozbun MA: Variable expression of some "housekeeping" genes during human keratinocyte differentiation. Anal Biochem 307: 341, 2002.
52. Zhong H and Simons JW: Direct comparison of GAPDH, beta actin, cyclophilin and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 259: 523-6, 1999.
53. Sen E, Bromberg-White JL and Meyers C: Genetic analysis of cis regulatory elements within the 5' region of the human papillomavirus Type 31b upstream regulatory region during different stages of the viral life cycle. J Virol 76: 4798-4809, 2002.
54. Bromberg-White J and Meyers C: The upstream regulatory region of HPV31 is insensitive to glucocorticoid induction. J Virol 76: 9702-9715, 2002.
55. Flores ER and Lambert PF: Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol 71: 7167-79, 1997.
56. Flanagan WM, Wagner RW, Grant D, Lin K -Y and Matteucci MD: Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nature Biotech 17: 48-52, 1999.
57. Ozbun MA and Meyers C: Human papillomavirus type 31b transcription during the differentiation-dependent viral life cycle. Curr Topics Virol 1: 203-217, 1999.
58. Androphy EJ, Hubbert NL, Schiller JT and Lowy DR: Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 6: 989-992, 1987.
59. Bedell MA, Jones, KH, Grossman, SG and Laimins LA: Identification of human papillomavirus type 18 transformation genes in immortalized and primary cells. J Virol 63: 1247-1255, 1989.
60. Dyson, N, Howley PM, Munger K and Harlow E: The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937, 1989.
61. Gage JR, Meyers C and Wettstein FO: The E7 proteins of the non-oncogenic HPV-6b and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 64: 723-730, 1989.
62. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH and Laimins LA: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53- mediated repression of transcription. EMBO J 11: 3045-3052, 1992.
63. McGlennen RC: Human papillomavirus oncogenesis. Clin Lab Med 20: 383-406, 2000.
64. Matlashewski G, Schneider J, Banks L, Jones N, Murray A and Crawford L: Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J 6: 1741-1746, 1987.
65. Vousden KH, Doniger J, Dipaolo JA and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3: 167-175, 1988.
66. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
67. Ferran MC and McBride A: Transient viral DNA replication and repression of viral transcription are supported by the C-terminal domain of the bovine papillomavirus Type 1 E1 protein. J Virol 72: 796-801, 1998.
68. Lambert PF and Howley PM: Bovine papillomavirus type 1 E1 replication-defective mutants are altered in their transcriptional regulation. J Virol 62: 4009-4015, 1988.
69. Schiller JT, Kleiner E, Androphy EJ, Lowy DR and Pfister, H: Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity. J Virol 63: 1775-1782, 1989.
70. Ozbun MA and Meyers C: Two novel promoters in the upstream regulatory region of human papillomavirus type 31b are negatively regulated by epithelial differentiation. J Virol 73: 3503-3510, 1999.
71. McLaughlin-Drubin ME, Christensen ND and Meyers C: Propagation, infection and neutralization of authentic HPV16 virus. Virology 322: 213-219, 2004.
72. McLaughlin-Drubin MR, Wilson S, Mullikin B, Suzich J and Meyers C: Human papillomavirus type 45 propagation, infection and neutralization. Virology 312: 1-7, 2003.
73. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM and Bennett CF: 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272: 11994-12000, 1997.
74. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, Ford C, Sasmor H and Anderson KP: Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 70: 5203-5212, 1996.
75. Cazenave C, Stein CA, Loreau N, Thuong NT, Neckers LM, Subasinghe C, Helene C, Cohen JS and Toulme JJ: Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynuleotides. Nucleic Acid Res 17: 4255-4273, 1989.
76. Mirabelli C K, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Des 6: 647-661, 1991.
77. Stein CA and Cohen JS: Phosphorothioate oligodeoxynucleotide analogs. In: J.S. Cohen (ed) Oligonucleotides: antisense inhibitors of gene expression, CRC Press, Boca Raton, FL, pp 97-117, 1989.
78. Lappalainen K, Pirilä L, Jääskeläinen I, Syrjänen K and Syrjänen S: Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anticancer Res 16: 2485-2492, 1996.
79. Levin AA: A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489: 69-84, 1999.
80. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF and Crooke ST: Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Des 12: 421-432, 1997.
81. Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB and Wagner H: Immunostimulatory CpG-oliogdeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 162: 2368-2374, 1999.